http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 09:15:20 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html <p>Creative Medical Technology Holdings (NASDAQ: CELZ) announced that all patients have been enrolled and treated across its FDA-cleared ADAPT clinical trial evaluating CELZ-201, also known as Olastrocel, for chronic lower back pain associated with degenerative disc disease, including participants in an opioid expansion cohort cleared by the FDA in June 2026.</p> <p>Olastrocel is a perinatal tissue-derived, allogeneic regenerative cell therapy administered through a minimally invasive, ultrasound-guided intramuscular procedure. The ADAPT trial was designed to assess safety, tolerability and preliminary efficacy of the therapy.</p> <p>Previously reported interim 180-day data showed a mean improvement in functional disability of 15.3 percentage points, with approximately 79% http://www.streetinsider.com/FDA/Creative+Medical+completes+enrollment+in+ADAPT+back+pain+trial/26954011.html Thu, 20 Aug 2026 09:15:20 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html <p align="center"><em>All patients enrolled and treated across original and FDA-cleared expansion cohorts</em></p> <p align="center"><em>Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain</em></p> <p align="center"><em>With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning</em></p> <p align="center"><em>Company believes reduced enrollment- and treatment-related expenditures should help preserve capital, extend operating runway and support continued Phase 3 preparation without the immediate need for additional fundraising</em></p> <p align="center"><em>Company remains fully engaged in patient follow-up, data collection, RMAT http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Successfully+Completes+Enrollment+and+Treatment+Across+Entire+FDA-Cleared+ADAPT+Trial%2C+Including+Opioid+Cohort%2C+Advancing+CELZ-201++Olastrocel+Toward+RMAT+Evaluat/26954008.html Thu, 20 Aug 2026 09:15:00 -0400 A.06822034 A.18970468 A.50210832 CELZ O.00199090 O.07026615 O.20026344 O.36684209 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jun+30/26892264.html si-local-file:///var/storage/secattach/20260807/26892264.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jun+30/26892264.html Fri, 07 Aug 2026 17:23:00 -0400 CELZ O.07026615